
Erasca, Inc. (NASDAQ:ERAS – Free Report) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Erasca in a report released on Friday, November 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.54) per share for the year, down from their previous forecast of ($0.51). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Erasca’s Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.88) EPS.
Erasca (NASDAQ:ERAS – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Several other equities analysts have also weighed in on ERAS. Bank of America raised their price objective on shares of Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Morgan Stanley increased their price target on shares of Erasca from $12.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Tuesday, September 8th. Finally, Guggenheim lifted their price objective on shares of Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.09.
Read Our Latest Research Report on Erasca
Erasca Stock Performance
Shares of NASDAQ ERAS opened at $15.11 on Tuesday. The business has a 50 day simple moving average of $14.94 and a 200 day simple moving average of $15.28. Erasca has a 52 week low of $2.52 and a 52 week high of $24.28. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of -15.26 and a beta of 0.68.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ERAS. Nykredit A S acquired a new position in Erasca during the 2nd quarter valued at $29,000. Allworth Financial LP bought a new position in Erasca in the second quarter worth $34,000. EverSource Wealth Advisors LLC lifted its position in Erasca by 77.8% in the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock worth $69,000 after purchasing an additional 1,859 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Erasca during the second quarter worth $80,000. Finally, KBC Group NV acquired a new stake in Erasca during the first quarter worth $81,000. 67.78% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Erasca
These are some of the ERAS headlines that stood out recently:
- Positive Sentiment: HC Wainwright retained its Buy rating and $22 price target. The firm’s outlook may help temper concerns about the company’s near-term losses.
- Neutral Sentiment: Erasca also plans to present ERAS-4001 combination data at a research symposium. The drug has shown encouraging preclinical activity, but it remains in early development and has not established clinical benefit. Erasca to Host Virtual Investor Event
- Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for 2026 through 2030, including FY2027 from $0.58 to $0.90 and FY2029 from $0.70 to $1.07. The revisions suggest greater anticipated losses and could weigh on sentiment, despite the continued Buy rating.
About Erasca
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Featured Articles
- Five stocks we like better than Erasca
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
